Publication

[Advanced Science] CRPC drugs work by either reducing dihydrotestosterone biosynthesis, or blocking androgen receptor (AR) signaling. Investigators demonstrated that AR inhibitor treatment gave rise to a drug-tolerant persister state.

[Oncogene] In vitro studies demonstrated that Myeloid differentiation factor-2 conferred invasiveness by activating MAPK and NF-kB signaling pathways and inducing epithelial–mesenchymal transition.

[The Prostate] PSMA was isolated from pooled seminal plasma from low-risk grade Groups 1 and 2 prostate cancer patients. Intact glycopeptides were analyzed by mass spectrometry to identify site-specific glycoforms.

[Aging-Us] Using bioinformatic analysis of data from the most recent databases, investigators extensively elucidated the role played by COL10A1 in terms of its expression patterns, prognostic implications, and immune efficacy across a pan-cancer spectrum.

[Cell] The authors presented Zman-seq, a single-cell technology recording transcriptomic dynamics across time by introducing time stamps into circulating immune cells, tracking them in tissues for days.

[Cell Reports Medicine] FLT3-L-dependent classical dendritic cells (cDCs) recruit anti-tumor and tumor-protecting lymphocytes. Investigators evaluated cancer growth in mice with low, normal, or high levels of cDCs.